DP110 | INFECTIONS AND IMMUNE RECONSTITUTION IN THE PHASE 3 CARTITUDE-4 TRIAL OF CILTACABTAGENE AUTOLEUCEL VS STANDARD CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AND 1–3 PRIOR LINES

Patients (pts) with multiple myeloma (MM) have high risk of infection. We characterize infections and immune reconstitution in pts receiving ciltacabtagene autoleucel (cilta-cel) vs standard care (SOC) treatment (tx) in CARTITUDE-4 (NCT04181827). Eligibility criteria were previously described. Cilta...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	R. Mina, M. Vogel, N.W.C.J. Van De Donk, J. Martínez-López, B. Dhakal, M. Dutka, L. Shune, C. Touzeau, X. Leleu, Y.C. Cohen, W. Alsdorf, K. Li, M. Zhao, Q. Li, A. Ghosh, N. Lendvai, A. Slaughter, C. Lonardi, V. Plaks, M. Koneru, N. Patel, E. Florendo, A. Oriol, R. Popat, P.J. Ho
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Ferrata Storti Foundation 2025-09-01
Reeks:	Haematologica
Online toegang:	https://haematologica.org/article/view/12604
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!